GNI Group Ltd. (2160.T)
- Previous Close
2,086.00 - Open
2,136.00 - Bid --
- Ask --
- Day's Range
2,100.00 - 2,182.00 - 52 Week Range
1,073.00 - 3,865.00 - Volume
1,048,900 - Avg. Volume
947,822 - Market Cap (intraday)
104.747B - Beta (5Y Monthly) 1.42
- PE Ratio (TTM)
10.78 - EPS (TTM)
194.88 - Earnings Date Aug 13, 2024 - Aug 19, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4,100.00
GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase III clinical trial for the treatment of liver fibrosis; and F573 that is in phase II for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.
www.gnipharma.comRecent News: 2160.T
Performance Overview: 2160.T
Trailing total returns as of 5/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2160.T
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2160.T
Valuation Measures
Market Cap
104.05B
Enterprise Value
86.76B
Trailing P/E
10.77
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.76
Price/Book (mrq)
3.01
Enterprise Value/Revenue
3.13
Enterprise Value/EBITDA
5.16
Financial Highlights
Profitability and Income Statement
Profit Margin
34.41%
Return on Assets (ttm)
8.02%
Return on Equity (ttm)
38.89%
Revenue (ttm)
27.75B
Net Income Avi to Common (ttm)
9.55B
Diluted EPS (ttm)
194.88
Balance Sheet and Cash Flow
Total Cash (mrq)
23.52B
Total Debt/Equity (mrq)
16.51%
Levered Free Cash Flow (ttm)
1.89B